Hyperliquid Strategies Posts $165M Loss as HYPE Grows

TLDR

• Hyperliquid Strategies reported a $165.4 million net loss for the nine months ended March 31.
• The company holds about 20 million HYPE tokens after recent treasury expansion.
• Hyperliquid deployed $216 million to acquire nearly 7.3 million HYPE tokens since December 2025.
• The firm recorded $64 million in unrealized losses tied to its HYPE holdings.
• Staking revenue reached $2.6 million for the three months ended March 31.

Hyperliquid Strategies Inc. reported a $165.4 million net loss for the nine months ended March 31. The Nasdaq-listed firm also confirmed it holds about 20 million HYPE tokens. The company expanded its treasury while scaling staking operations and restructuring legacy assets.

The company disclosed that it deployed $216 million to acquire about 7.3 million HYPE tokens since December 2025. It built its position after going public through a merger with Sonnet BioTherapeutics last year. The firm stated that it aims to maximize shareholder value through staking, yield optimization, and ecosystem participation.

Chief Executive Officer David Schamis addressed the company’s progress in the quarterly filing. He said, “This quarter marked meaningful progress in establishing HSI as the leading public vehicle for capital-efficient HYPE exposure.” He added that the company increased its treasury and strengthened its operational focus.

Hyperliquid Expands HYPE Treasury and Validator Operations

Hyperliquid Strategies confirmed it scaled its HYPE treasury during the fiscal third quarter. The firm now holds about 20 million HYPE tokens, including recent acquisitions. It allocated $216 million to purchase roughly 7.3 million tokens since inception.

Schamis said the company aligned its strategy with Hyperliquid’s deflationary mechanics and ecosystem growth. He stated, “We materially scaled our HYPE treasury and announced our validator partnership with Unit.” He also confirmed that the company had completed most of the disposition of its legacy biotechnology operations.

The company reported $64 million in net unrealized losses tied to its HYPE holdings. It recorded those losses during the nine-month reporting period. However, it continued staking activities to generate recurring revenue.

Staking revenue reached $2.6 million for the three months ended March 31. Interest income contributed another $1 million during the same period. Operating expenses totaled $7.2 million for the quarter.

PURR Share Repurchases and Financial Performance Update

Hyperliquid Strategies deployed $10.5 million to repurchase about 3 million PURR shares. The company paid an average price of $3.42 per PURR share. It executed those repurchases as part of its capital allocation strategy.

The company maintains a $103 million cash position for future treasury deployments. It stated that it will use the funds for token acquisitions, share repurchases, and corporate expenses. The balance sheet reflects liquidity to support ongoing operations.

The firm attributed its $165.4 million net loss primarily to three factors. It recorded $64 million in unrealized HYPE losses and a $35.6 million one-time write-off linked to Sonnet. It also reported a $60.5 million increase in deferred tax expense.

In March, the company launched options trading for its common stock PURR on the Nasdaq Options Market. The launch expanded trading instruments available to market participants. The update marked the latest development in the company’s public market operations.

The post Hyperliquid Strategies Posts $165M Loss as HYPE Grows appeared first on Blockonomi.